Kazia Therapeutics Presents Phase I Data Evaluating Concurrent Paxalisib And Radiation Therapy In Patients With Solid Tumor Brain Metastases Or Leptomeningeal Metastases Harboring PI3K Pathway Mutations At American Society For Radiation Oncology 66th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Kazia Therapeutics presented promising Phase I data at the American Society for Radiation Oncology meeting, showing that treatment with paxalisib and radiotherapy achieved a 67% partial response in patients with brain metastases. This compares favorably to historical response rates for radiation therapy alone.
October 02, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kazia Therapeutics' Phase I trial data shows a 67% partial response rate for paxalisib combined with radiotherapy in brain metastases patients, outperforming historical radiation therapy results.
The positive Phase I trial results for paxalisib, showing a 67% partial response rate, suggest a potential competitive advantage over traditional radiation therapy. This could lead to increased investor interest and a positive short-term impact on KZIA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100